Medication info
DanuMet XR Sustained Release Tablet 50/500 mg

DanuMet XR Sustained Release Tablet 50/500 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.69mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
K.S. Pharmaceutical Co., Ltd.
Appearance
Light blue, bilaterally convex oval sustained-release film-coated tablet
Packaging
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Approval status
Active

MFDS item code 202300587 · Approved 2023.02.17 · Insurance code 059001150

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this drug should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this drug must be swallowed whole and should not be split, crushed, ground, or chewed. The 100/1000 mg extended-release tablets of this drug are taken once daily, 1 tablet per dose. Patients taking the 50/500 mg or 50/1000 mg extended-release tablets of this drug take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug. 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this drug is sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. - Patients who were receiving immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this drug 50/1000 mg extended-release tablets once daily. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Treatment should not be initiated with this drug because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug must be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin.

Ingredients

Manufacturer
K.S. Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication helps control blood sugar levels in patients with type 2 diabetes by combining sitagliptin and metformin. When used alongside dietary and exercise therapies, it aids in effectively managing blood sugar levels, contributing to the prevention of diabetes complications and overall health improvement. Therefore, it is used to enhance blood sugar control in type 2 diabetes patients.

How to take

Adult dose

In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this drug should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this drug must be swallowed whole and should not be split, crushed, ground, or chewed. The 100/1000 mg extended-release tablets of this drug are taken once daily, 1 tablet per dose. Patients taking the 50/500 mg or 50/1000 mg extended-release tablets of this drug take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug. 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this drug is sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. - Patients who were receiving immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this drug 50/1000 mg extended-release tablets once daily. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Treatment should not be initiated with this drug because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug must be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin.

Precautions

This medication contains sitagliptin and metformin hydrochloride and is used for diabetes treatment. First, the sitagliptin component can rarely cause serious allergic reactions such as anaphylaxis, angioedema, and skin exfoliative disease, so if these symptoms occur, stop taking the medication immediately and seek medical attention. Also, acute pancreatitis can occur, so it is important to inform medical personnel immediately if abdominal pain, vomiting, or severe abdominal discomfort occurs. The metformin hydrochloride component can cause a rare but fatal side effect known as lactic acidosis, so patients with impaired kidney function, liver disease, severe infections, or dehydration should not take this medication. In particular, it should not be administered to patients with moderate or severe renal impairment, acute heart failure, acute myocardial infarction, sepsis, or pregnant or nursing women. During treatment with this medication, renal function should be regularly monitored, and should renal function deteriorate rapidly, the medication should be temporarily discontinued. Additionally, hypoglycemia may occur due to irregular meals, excessive exercise, or interactions with other medications, so caution is advised. This medication contains the dye Red No. 40, so it should be used cautiously in individuals with allergies to this component. Before undergoing surgery or imaging tests with contrast agents, this medication should be stopped for a period of time, and after kidney function is confirmed to be normal following surgery, it can be resumed. It is advisable to avoid alcohol consumption during treatment with this medication, as especially excessive acute or chronic alcohol intake can increase the risk of lactic acidosis. Lastly, this medication is not recommended for children under 18 years of age or pregnant women, and caution is needed for the elderly as they may have reduced kidney function. If any unusual symptoms or suspected side effects occur during treatment, consult a doctor or pharmacist immediately.

Side effects

Anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory tract infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, peripheral edema, hypoglycemia, severe hypoglycemia, arthralgia with severe and disabling symptoms, bullous pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, elevated liver enzymes, acute renal failure, constipation, rash, urticaria, cutaneous vasculitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. It is best to maintain a storage temperature between 1 degree and 30 degrees Celsius at room temperature. This will help to preserve the effectiveness of the medication.

Appearance and packaging

Appearance

Light blue, bilaterally convex oval sustained-release film-coated tablet

Package unit

Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.